PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
59.45%
Revenue growth similar to CRON.TO's 60.92%. Walter Schloss would see if both companies share industry tailwinds.
-53.84%
Both firms have negative gross profit growth. Martin Whitman would question the sector’s viability or cyclical slump.
-103.69%
Negative EBIT growth while CRON.TO is at 1969.01%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-103.69%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
153.01%
Positive net income growth while CRON.TO is negative. John Neff might see a big relative performance advantage.
141.84%
Positive EPS growth while CRON.TO is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.
141.84%
Positive diluted EPS growth while CRON.TO is negative. John Neff might view this as a strong relative advantage in controlling dilution.
8.51%
Share reduction more than 1.5x CRON.TO's 52.85%. David Dodd would see if the company is taking advantage of undervaluation to retire shares.
8.22%
Diluted share reduction more than 1.5x CRON.TO's 38.21%. David Dodd would validate if the company is aggressively retiring shares or limiting option exercises.
No Data
No Data available this quarter, please select a different quarter.
89.50%
Positive OCF growth while CRON.TO is negative. John Neff would see this as a clear operational advantage vs. the competitor.
24.16%
Positive FCF growth while CRON.TO is negative. John Neff would see a strong competitive edge in net cash generation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
63.82%
3Y CAGR of 63.82% while CRON.TO is zero. Bruce Berkowitz would see if small gains can accelerate to a more decisive lead.
-109.34%
Negative 10Y OCF/share CAGR while CRON.TO stands at 0.00%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
-273.64%
Both show negative mid-term OCF/share growth. Martin Whitman might suspect a challenged environment or large capital demands for both.
-202.53%
Both face negative short-term OCF/share growth. Martin Whitman would suspect macro or cyclical issues hitting them both.
3051.78%
10Y net income/share CAGR of 3051.78% while CRON.TO is zero. Bruce Berkowitz would see if minor gains can compound into a bigger lead over time.
11082.24%
Below 50% of CRON.TO's 68335.89%. Michael Burry would worry about a substantial lag vs. the competitor’s profit ramp-up.
2188.69%
3Y net income/share CAGR 1.25-1.5x CRON.TO's 1784.68%. Bruce Berkowitz might see new markets, M&A, or better cost discipline driving the difference.
3410.56%
Equity/share CAGR of 3410.56% while CRON.TO is zero. Bruce Berkowitz might see a slight advantage that can compound significantly over 10 years.
16854.11%
5Y equity/share CAGR is in line with CRON.TO's 16490.98%. Walter Schloss would see parallel mid-term profitability and retention policies.
448.58%
Below 50% of CRON.TO's 918.25%. Michael Burry suspects a serious short-term disadvantage in building book value.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
7.98%
AR growth is negative/stable vs. CRON.TO's 232.30%, indicating tighter credit discipline. David Dodd confirms it doesn't hamper actual sales.
13.55%
Inventory shrinking or stable vs. CRON.TO's 43.44%. David Dodd confirms the company’s supply-chain is more efficient if sales are unaffected.
26.26%
Asset growth above 1.5x CRON.TO's 0.56%. David Dodd checks if M&A or new capacity expansions are value-accretive vs. competitor's approach.
10.83%
Positive BV/share change while CRON.TO is negative. John Neff sees a clear edge over a competitor losing equity.
-3.57%
We’re deleveraging while CRON.TO stands at 50.49%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
128.48%
R&D growth drastically higher vs. CRON.TO's 100.93%. Michael Burry fears near-term margin erosion unless breakthroughs are imminent.
15.04%
SG&A declining or stable vs. CRON.TO's 93.45%. David Dodd sees better overhead efficiency if it doesn't hamper revenue.